Insulet Corporation(PODD)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Latest News & Analysis
Insulet (PODD): Omnipod 5 Expansion, Financial Outlook
Analysis of Insulet (PODD): Omnipod 5 expansion, financial health, and competitive landscape amidst macroeconomic headwinds. Key insights for investors.
Insulet (PODD): Expansion, Debt Strategy, and Market Challenges
Insulet (PODD) navigates expansion, debt, and competition in automated insulin delivery. Australian launch, trial data, and a $450M note offering shape its trajectory.
Insulet (PODD): Omnipod 5, RADIANT Trial, and Financial Strategy
Analysis of Insulet (PODD): Omnipod 5 adoption, RADIANT trial, $450M senior notes, and financial strategies shaping its growth and market position.
Insulet (PODD): Debt Offering, Investor Day, and Omnipod's Market Impact
Insulet (PODD) navigates a dynamic landscape with a $450M debt offering, upcoming Investor Day, and sustained Omnipod demand, showcasing resilience and growth potential.
Insulet (PODD) Q4 Earnings: Omnipod 5 Growth & Investor Day Preview
Insulet (PODD) surges +3.8% following strong Q4 earnings, fueled by Omnipod 5 adoption. Investor Day on June 5th to reveal future strategies.
Insulet (PODD) Q4 2024 Earnings: Growth, Challenges, and Outlook
Insulet's Q4 2024 earnings reveal growth, but EPS decline raises concerns. Omnipod 5 drives expansion, while competition and market trends present challenges.
Insulet (PODD) Q4 2024 Earnings: Omnipod 5 Drives Growth, Competition Intensifies
Insulet's Q4 2024 earnings showcased strong revenue growth driven by Omnipod 5, but the stock price declined despite positive results. Competition intensifies.
Insulet (PODD) Q4 2024 Earnings: Omnipod 5 Growth and Market Analysis
Insulet's Q4 2024 earnings beat expectations, driven by Omnipod 5 demand. Despite a stock dip, analysts see continued growth in the evolving diabetes market.
Insulet (PODD) Q4 2024: Earnings, Market Reaction, and Future Outlook
Insulet (PODD) Q4 2024 earnings beat estimates, driven by Omnipod 5. Despite this, PODD stock fell, raising investor concerns about future growth. A detailed analysis follows.
Insulet Q4 Earnings: Strong Revenue, Margins Amid Stock Decline
Insulet reported robust Q4 2024 earnings driven by Omnipod 5 and European expansion, yet stock declined due to softer future revenue guidance.
Insulet's Omnipod 5: European Expansion and Q4 Earnings Outlook
A data-driven analysis of Insulet (PODD)'s Omnipod 5 expansion in Europe and key metrics ahead of its Q4 2024 earnings report.